Uses
BRIVIACT is indicated for the treatment of partial-onset seizures in patients 1 month of age and older.
Source: US FDA prescribing information
- Presentations
- 14
- Brands
- 1
- Manufacturers
- 1
- Available from stock
- 0
Brivaracetam is a prescription medicine indicated for the treatment of partial-onset seizures in patients 1 month of age and older. It is available as tablets, oral solution and injection for intravenous use. MedsAcross supplies Brivaracetam for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Key facts
- Pharmacological class
- Epoxide Hydrolase Inhibitors
- ATC classification
- N03AX23 Brivaracetam · Anticonvulsant agent, subgroup N03AX
- US FDA first approval
- 18 February 2016
- EU status
- Authorised
- Orphan designation
- No
- WHO essential medicine
- Not recorded
- India (CDSCO)
- Not yet confirmed against CDSCO approval lists
- Routes
- Oral, Intravenous
- Dosage forms
- Tablet, Oral solution, Injection, Injectable suspension
- Identifiers
- UNII U863JGG2IARxCUI 1739745CAS 357336-20-0DrugBank DB05541Q408099
Clinical information
From the regulator-approved product information. Each section names its source.
How it works
The precise mechanism by which BRIVIACT exerts its anticonvulsant activity is not known. Brivaracetam displays a high and selective affinity for synaptic vesicle protein 2A (SV2A) in the brain, which may contribute to the anticonvulsant effect.
Source: US FDA prescribing information
Dosing overview
Adults (16 Years and Older): The recommended starting dosage for monotherapy or adjunctive therapy is 50 mg twice daily (100 mg per day). Based on individual patient tolerability and therapeutic response, the dosage may be adjusted down to 25 mg twice daily (50 mg per day) or up to 100 mg twice daily (200 mg per day). Pediatric Patients (1 Month to less than 16 Years): The recommended dosage is based on body weight and is administered orally twice daily. Injection: for intravenous use only when oral administration is temporarily not feasible, dosing is the same as oral regimen. Hepatic Impairment: Dose adjustment is recommended for all stages of hepatic impairment.
Source: US FDA prescribing information
Contraindications
Hypersensitivity to brivaracetam or any of the inactive ingredients in BRIVIACT (bronchospasm and angioedema have occurred). Hypersensitivity to brivaracetam or any of the inactive ingredients in BRIVIACT.
Source: US FDA prescribing information
Warnings and precautions
Suicidal Behavior and Ideation: Monitor patients for suicidal behavior and ideation. Neurological Adverse Reactions: Monitor for somnolence and fatigue, and advise patients not to drive or operate machinery until they have gained sufficient experience on BRIVIACT. Psychiatric Adverse Reactions: Behavioral reactions including psychotic symptoms, irritability, depression, aggressive behavior, and anxiety, monitor patients for symptoms. Hypersensitivity: Bronchospasm and Angioedema: Advise patients to seek immediate medical care. Discontinue and do not restart BRIVIACT if hypersensitivity occurs. Serious Dermatologic Reactions: Discontinue BRIVIACT unless an alternative etiology is established. Withdrawal of Antiepileptic Drugs: BRIVIACT should be gradually withdrawn.
Source: US FDA prescribing information
Side effects
The following serious adverse reactions are described elsewhere in labeling: Suicidal Behavior and Ideation Neurological Adverse Reactions Psychiatric Adverse Reactions Hypersensitivity: Bronchospasm and Angioedema Serious Dermatologic Reactions Withdrawal of Antiepileptic Drugs Adults: Most common adverse reactions (at least 5% for BRIVIACT and at least 2% more frequently than placebo) are somnolence/sedation, dizziness, fatigue, and nausea/vomiting. Pediatric Patients: Most common adverse reactions are similar to those seen in adult patients.
Source: US FDA prescribing information
Interactions
Rifampin: Because of decreased concentrations, increasing BRIVIACT dosage in patients on concomitant rifampin is recommended. Carbamazepine: Because of increased exposure to carbamazepine metabolite, if tolerability issues arise, consider reducing carbamazepine dosage in patients on concomitant BRIVIACT. Phenytoin: Because phenytoin concentrations can increase, phenytoin levels should be monitored in patients on concomitant BRIVIACT. Levetiracetam: BRIVIACT had no added therapeutic benefit when co-administered with levetiracetam.
Source: US FDA prescribing information
Storage
Store at 25°C (77°F), excursions permitted between 15°C to 30°C (59°F to 86°F). See USP Controlled Room Temperature. Do not freeze BRIVIACT injection or oral solution.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
All presentations
14 presentations of Brivaracetam, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Brivaracetam 100 mg tabletOralGeneric name | — | US FDA | Available on request |
| Brivaracetam 25 mg tabletOralGeneric name | — | US FDA | Available on request |
| Brivaracetam 50 mg tabletOralGeneric name | — | US FDA | Available on request |
| Brivaracetam 75 mg tabletOralGeneric name | — | US FDA | Available on request |
| Brivaracetam 10 mg tabletOralGeneric name | — | US FDA | Available on request |
| Brivaracetam 10 mg/mL oral solutionOralGeneric name | — | US FDA | Available on request |
| Brivaracetam 50 mg/5 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Briviact 100 mg tabletOral | UCB | US FDA | Available on request |
| Briviact 25 mg tabletOral | UCB | US FDA | Available on request |
| Briviact 50 mg tabletOral | UCB | US FDA | Available on request |
| Briviact 10 mg tabletOral | UCB | US FDA | Available on request |
| Briviact 10 mg/mL oral solutionOral | UCB | US FDA | Available on request |
| Briviact 50 mg/5 mL injectable suspensionIntravenous | UCB | US FDA | Available on request |
| Briviact 75 mg tabletOral | UCB | US FDA | Available on request |
Brands by market
1 brand names across 1 markets.
United States
Manufacturers
Regulatory status
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Conditions
Conditions linked to Brivaracetam in public data. This is not a list of approved uses, see the clinical information.
Questions and answers
Is Brivaracetam available for export from India?
Yes, on request. MedsAcross lists 14 presentations of Brivaracetam and sources them for licensed hospitals, importers and physicians against valid import documents.
What brand names does Brivaracetam have?
The catalogue lists 1 brand names for Brivaracetam, including Briviact.
Is Brivaracetam approved by the US FDA?
Yes. The US FDA first approved Brivaracetam on 18 February 2016, according to Drugs@FDA.
Is Brivaracetam authorised in the European Union?
Yes. Brivaracetam has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
Does Brivaracetam need cold chain shipping?
No listed presentation of Brivaracetam is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Which ATC class is Brivaracetam in?
Brivaracetam is classified under ATC code N03AX23 (Brivaracetam).
References
- Briviact prescribing information (UCB). U.S. National Library of Medicine, DailyMed. Retrieved 5 November 2026
- Briviact (in Italy: Nubriveo): European public assessment report (EPAR). European Medicines Agency. Retrieved 27 January 2026
Request Brivaracetam for export supply
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.